ADVERTISEMENT
Friday, January 27th 2023
Today's Paper
The Kashmir Monitor
🔒 Log in
💲 Contribute
No Result
View All Result
  • LatestLive
  • News
  • Kashmir
  • India
  • World
  • Politics
  • Editorial
  • Business
  • Sports
  • Education
  • Health
  • Tech-Film
  • Auto
  • Crypto
  • Travel
The Kashmir Monitor
  • LatestLive
  • News
  • Kashmir
  • India
  • World
  • Politics
  • Editorial
  • Business
  • Sports
  • Education
  • Health
  • Tech-Film
  • Auto
  • Crypto
  • Travel
The Kashmir Monitor
No Result
View All Result
Home Health

`CoVac-1′: New Covid vaccine may protect cancer patients

Monitor News Desk by Monitor News Desk
Apr. 14, 2022 Updated 10:16 am. IST
A A
Get vaccinated or lose jobs: Check out Google’s new workplace rules


German researchers have developed a new Covid vaccine that can protect people with weaker immune systems including cancer patients, particularly those with B-cell deficiencies.

ADVERTISEMENT

B cells are the immune cells responsible for antibody-mediated responses, which is the main target of all currently approved Covid vaccines. But cancer patients remain immunocompromised as treatments such as chemotherapies and some immunotherapies destroy B cells.

AlsoRead

WATCH: Sania Mirza bids tearful adieu to Grand Slams

WATCH: Kashmir’s ‘Peter Dinklage’ enacts ‘Pathaan’ song in snow

Munna bhai and Circuit reunite! Sanjay Dutt announces new film

The results presented at the recent AACR Annual Meeting 2022, showed that the vaccine CoVac-1 induced T-cell immune responses in 93 percent of patients with B-cell deficiencies, including many patients with leukemia and lymphoma.

“To our knowledge, CoVac-1 is currently the only peptide-based vaccine candidate specifically developed and evaluated for immunocompromised patients,” said Juliane Walz, Professor at the University Hospital Tubingen in Germany.

The CoVac-1 vaccine enhances the response from T cells – another type of immune cell, and “previous evidence has shown that T cells can combat Covid-19 even in the absence of neutralizing antibodies,” said Claudia Tandler, a graduate student at the University. “T-cell immune responses against SARS-CoV-2 are of particular importance for patients with B-cell deficiencies, who develop very limited antibody responses after infection or vaccination,” Tandler added.

ADVERTISEMENT

To develop CoVac-1, Tandler and the team chose six specific antigens from different parts of the virus (not limited to spike protein as the current vaccines) to make up their vaccine.

CoVac-1 is a peptide vaccine, meaning that the protein pieces are injected directly, rather than being encoded via mRNA.

“CoVac-1-induced T-cell immunity is far more intense and broader, as it is directed to different viral components than mRNA-based or adenoviral vector-based vaccines that are limited to the spike protein and are thus prone to loss of activity due to viral mutations,” Tandler said.

In the phase I clinical trial, the researchers recruited 14 patients with a B-cell deficiency, including 12 patients with leukemia or lymphoma. The patients were given a single dose of CoVac-1 and monitored for up to six months for safety and immunogenicity. Notably, 64 percent of the patients in this study had been previously vaccinated with an approved SARS-CoV-2 vaccine that failed to elicit a humoral immune response.

Fourteen days after vaccination, T-cell immune responses were observed in 71 percent of patients, which rose to 93 percent of patients, 28 days after vaccination.


Facebook Twitter Youtube Instagram Whatsapp
Logo

© 2023 The Kashmir Monitor - All rights reserved.

No Result
View All Result
  • Home
  • Latest News
  • Lead Stories
  • News
  • Kashmir
  • India
  • World
  • Politics
  • Education
  • Business
  • Environment
  • Health
  • Sports
  • Editors’ Picks
  • Videos
  • Lifestyle
  • Tech-Film
  • Today’s Paper

© 2023 The Kashmir Monitor - All rights reserved.